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Restrictions on interactions between doctors and
industry could ultimately hurt patients
Carey Kimmelstiel, MD, Boston, Mass
Physician-industry collaboration has led to a diverse array of therapeutic advancements that have benefitted a broad
spectrum of patient populations. Evolving regulations, both institutional and governmental, aiming to govern interac-
tions between physicians and pharmaceutical and medical device manufacturers have become increasingly prevalent.
Emerging data suggest that restrictions on physician-industry collaboration have the potential to harm patient care by
degrading innovation and stifling medical education. The following article reviews the effects of legislation on medical
innovation as well as the impact on continuing medical education. (J Vasc Surg 2011;54:12S-4S.)
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mThe overwhelming majority of therapeutic medical ad-
vances – be they pharmacologic or device – are developed as
a consequence of collaboration between medical industry
with physician partners. This symbiotic relationship has led
to beneficial effects on patient outcomes. When examining
end points such as death from cardiovascular causes as a
metric, mortality rates have precipitously declined over the
last half of the prior century as a consequence of the
development and prescription of medications and devices
developed via physician-industry collaboration.1-3
One concern relating to the current era of enhanced
regulation of industry-physician interaction is the potential
for disruption of collaboration with resultant reduction in
innovation leading to a retardation of therapeutic advance-
ment.
REGULATIONS
An increasing array of regulations by governmental
bodies and individual institutions affect all medical practi-
tioners. While a comprehensive review of these regulations
is beyond the scope of this article, a discussion of these
mandates appears elsewhere in this supplement.
As relates to individual state laws, seven states (Califor-
nia, Maine, Massachusetts, Minnesota, Nevada, Vermont,
West Virginia) and the District of Columbia have enacted
their own versions of “Sunshine Laws” which generally
include mandatory codes of conduct, “gift bans,” public
disclosures, and compliance requirements. The Federal
Physician Payment Sunshine Law was passed by Congress
in March 2010. It requires public disclosure of payments or
transfer of value to a physician or teaching hospital by
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12Sedical device and pharmaceutical companies with annual
eporting to the Department of Health and Human Ser-
ices beginning in March 2013.4 These reports will indicate
ot only the amount of payment, but their description as
ell (eg, consulting, honoraria, grant, etc).
Massachusetts provides an interesting case study in the
volution of individual state regulation concerning the
nteractions between industry and physicians. The Pharma-
eutical and Medical Device Manufacturer Code of Con-
uct (105 CMR 910.000; also known as the “Gift Ban”)
as enacted under broader health care legislation and is
rguably the most far-reaching attempt made by any state
egislature to govern the interactions of physicians with
edical industry. This legislation applies to companies
oing business within the Commonwealth of Massachu-
etts, regardless where the firm is headquartered, and ap-
lies to all industry activities that either take place in Mas-
achusetts or involve a Massachusetts licensed health care
rovider (eg, at a convention taking place outside of Mas-
achusetts). This law regulates industry marketing practices
hat are not otherwise illegal (eg, meals, entertainment),
stablishes a regimen for reporting and disclosure of indus-
ry payments, mandates industry compliance programs
ith the imposition of financial penalties, and implements
trict limits on continuing medical education (CME) and
ther professional academic presentations.
There are numerous anecdotes that reflect the unin-
ended, but quite impactful consequences of this legisla-
ion. Once enacted, industry-sponsored conferences within
assachusetts were markedly curtailed.5,6 Although not
pecifically prohibited by the “gift ban” legislation, there
ave been several reported instances where grants to sup-
ort visiting professor programs and other academic edu-
ational pursuits, including clinical trials, have been can-
eled in Massachusetts due to concerns regarding not only
he specifics of the new legislation, but the resources re-
uired to ensure adherence to it.5,6 At medical conferences,
n some cases, companies sponsoring events in conjunction
ith the conference have posted signs advising health care
rofessionals from Massachusetts, Minnesota, and Ver-
ont not to participate due to fear of violating the legisla-ive reporting requirements.
a
C
O
t
c
f
i
9
f
e
i
I
f
O
F
a
y
b
r
c
c
G
W
t
d
l
H
i
t
c
c
d
i
l
w
t
h
r
u
l
s
G
o
t
G
r
e
G
t
y
w
a
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 18S Kimmelstiel 13SCME
Total support for CME has declined in large measure
due to a reduction in industry support for these programs.7
With no reliable source of funding to fill the consequent
financial void, educational programs will likely continue to
diminish in the near-term.
The individual state laws such as those enacted in
Massachusetts and Minnesota, which have led to a defacto
cessation in industry funded postgraduate medical educa-
tional events, appear to be predicated on allegations of
potential corruption, which are used as a justification for
enhanced oversight. The inherent premise underpinning
support for such legislation is that marketing to and collab-
oration with physicians by industry cause clinicians unwit-
tingly to prescribe or promote unsafe and/or unnecessarily
expensive products. In addition, the thinking also seems to
be that payments to physicians for time or work, be that
education or research, leads to the appearance of conflicts
of interest, which erode professionalism and the public
trust of medical caregivers and industry. These suppositions
ignore the reality that physician prescribing patterns are
constrained by formulary-tiered policies of health plans.
Additionally, cost-containment as relates to pharmaceutical
prescribing is a questionable goal in a state such as Massa-
chusetts, where almost three-quarters of all prescribed
medications are filled with generic agents.8
The increased scrutiny of industry-physician collabora-
tion in concert with the previously mentioned regulations
has led to a reduction in industry support of CME. The
question that requires answering is whether commercial
support leads to bias in CME presentations.
The Accreditation Council on Continuing Medical Ed-
ucation commissioned a study which sought to analyze the
research literature concerning the relationship between
commercial support and bias in CME.9 This report found
no empiric evidence to support or refute the hypothesis that
CME activities are biased. The investigators went on to
conclude from their analysis that there was limited evidence
suggesting that commercially supported CME activities can
effectively change physician prescribing practices – a finding
that was thought to be consistent with prior studies docu-
menting that CME alters physician practices and improves
patient care. The authors went on to conclude that the
majority of physicians understand the potential for bias but
do not believe that CME activities are slanted by commer-
cial support and that they, the clinicians, are capable of
making clinical decisions in the best interests of their pa-
tients.9
Since the publication of this study, there have been
several other published studies examining the topic of bias
in commercially supported CME activities. Ellison and
colleagues surveyed more than 1.5 million physicians par-
ticipating in on-line CME.10 They documented that 1%
of physician participants reported bias in the presentations
in which they participated.10 There was, however, a small
but significant excess of bias reporting in commercially
supported activities (0.8% vs 0.5%; P .001).10 Kawczak et tl analyzed data from almost 100,000 participants in 346
ME programs conducted through the Cleveland Clinic.
n average, 98.4% of participants reported that the activi-
ies were free from bias with no signal of an effect of
ommercial support on bias perception.11 Another report
rom the University of California at San Francisco, examin-
ng 213 live CME courses, documented that a median of
7% of respondents noted that CME activities were free
rom commercial bias.12 There was no association between
xtent of commercial support and degree of perceived bias
n this study.12
NNOVATION
History has shown that the clinical benefit that results
rom medical innovation is unpredictable and infrequent.
nly one out of approximately 8000 compounds achieves
ood and Drug Administration (FDA) approval after an
verage of 16 years and approximately $1.0 billion.13 In the
ear following the gift ban legislation in Massachusetts, lay
usiness publications have documented a loss of medically-
elated jobs and reluctance on the part of sponsors to
onduct research in Massachusetts, citing the effort and
osts involved to ensure compliance.5,6
In an effort to assess the impact of the Massachusetts
ift Ban Legislation on physician-industry collaboration,
olf performed a literature review and surveyed 143 indus-
ry stakeholders, including medical device manufacturers,
istributors, academic medical centers, venture capitalists,
awyers, consulting firms, the Department of Public
ealth, and physicians. This study documented that 70% of
ndustry-stakeholder respondents noted an impaired ability
o collaborate with physicians, and 83% reported a de-
reased interest in collaborating with Massachusetts physi-
ians.14 The overwhelming majority of physician respon-
ents described an impaired ability to collaborate with
ndustry, with almost three-fourths noting that the gift ban
egislation had severely impaired their ability to interact
ith industry. This study also reported that more than
hree-fourths of physicians reported that the Gift Ban law
ad impaired physician education, while more than half also
eported that because of constraints imposed on postgrad-
ate medical education, there would be a resultant negative
ong-term impact on patient care. Almost half of the phy-
ician respondents reported that, in the year following the
ift Ban, there had been a reduced exposure to therapeutic
ptions involving newer devices. Perhaps most troubling is
hat 83% of respondents noted that in the time since the
ift Ban legislation had been enacted, there had been a
esultant decrease in funding for fellowships, non-CME
ducation, and research.14
ENERAL THOUGHTS ON INNOVATION
A recent issue ofNewsweekmagazine decried the reduc-
ion in medical innovation documenting that between the
ears 1996 and 1999, the FDA approved 157 new drugs,
hile one decade later, between 2006 and 2009, the
gency approved 74.15 A recent report documented that
he FDA had approved only 21 new drugs in 2010.16 A poll
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ican public is concerned about the pace of medical and
health research and that 94% of those polled supported the
collaboration of physicians, private industry, government,
and universities to facilitate the development of therapeutic
advancements.17 While this decline in new drug approvals
is likely not entirely due to isolation policy and concern
about unethical relationships, increasingly tight restrictions
on free trade and the interaction between prescribers and
manufacturers reduce innovation efficiency and productiv-
ity. One might pose a question that follows as the logical
corollary to the decline in new drug approvals: Which
innovation construct delivers potential cures to patients in
the timeliest manner, and do these policies serve those
characteristics? The current innovation environment is
made more complex by intense regulatory risk sensitivity
with less regard to corresponding benefit as well as by
prolonged reimbursement decisions by Centers for Medi-
care and Medicaid Services. The risk is that as investment
outcome becomes more uncertain, capital and resources
might depart medicine and migrate to safer investment
havens with greater potential return on investment.
GENERAL THOUGHTS ON “CONFLICT OF
INTEREST”
The term “conflict of interest” is used freely and, in my
view and that of others, represents a framing bias.18 It
should be remembered that when two parties interact in a
professional relationship, interests are rarely perfectly
aligned. Conflict allegations are one-sided views of rela-
tionships or situations that inherently suggest that risks
eclipse benefits; this itself represents a fundamentally biased
view. The term “conflict of interest” is an epithet that by
terminological fiat makes every instance of overlapping
interests presumptively malignant by default.18 Accepting
the frame of “conflict” imposes an impossible task of prov-
ing a negative based on invisible motives.
CONCLUSIONS
We are living in an era of enhanced scrutiny regarding
the interactions of physicians and medical industry. The
limited data currently available suggest that states which
have legislated “sunshine provisions” have experienced a
number of untoward, unintended consequences. These
include reduced interactions between physicians with in-
dustry partners as well as reductions in opportunities for
postgraduate medical education. Together, these effects
threaten the pace of medical innovation and ultimately
patient care. What is problematic is that legislative agendas
that propose comprehensive physician disengagement from
interactions with industry do so without offering estimates
of its risks or costs. Given the measurable decline in CME
support and the apparent reduction in innovation that has
resulted in states where “gift bans” have been enacted, the
question that needs to be answered is, what is the quanti-
fiable benefit that makes such prophylaxis worthwhile? As Se move forward, all interested parties should work to-
ether to achieve the goals of enhancing transparency of
orking relationships without threatening the pace of ther-
peutic progress and the evolution of improvements in
atient care.
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